Biologic response modifiers in pediatric cancer.
Biologic response modifiers are becoming an important addition to surgery, chemotherapy, and radiotherapy in the management of cancer. As this field of research grows and expands, more biologic response modifiers will be incorporated into therapeutic regimens. By stimulating the immune system to eradicate minimal residual disease, these agents may improve the disease-free and long-term survival rates of patients with a variety of malignancies. The challenge is to incorporate biologic response modifiers into the treatment armamentarium in ways that will maximize their tumorigenicity.
Worth
L L
LL
Department of Pediatrics, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Jeha
S S
SS
Kleinerman
E S
ES
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000601:surgery; D001932:Brain Neoplasms / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D002648:Child; D002675:Child, Preschool; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D016207:Cytokines / Q000627:therapeutic use; D015195:Drug Design; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods; D007223:Infant; D007378:Interleukins / Q000627:therapeutic use; D015474:Isotretinoin / Q000627:therapeutic use; D008081:Liposomes; D009369:Neoplasms / Q000188:drug therapy*; D009447:Neuroblastoma / Q000188:drug therapy; D012516:Osteosarcoma / Q000188:drug therapy / Q000601:surgery; D010713:Phosphatidylcholines / Q000627:therapeutic use; D010714:Phosphatidylethanolamines / Q000008:administration & dosage / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000627:therapeutic use; D016879:Salvage Therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D016207:Cytokines; D016298:Hematopoietic Cell Growth Factors; D007155:Immunologic Factors; D007378:Interleukins; D008081:Liposomes; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D010715:Phosphatidylglycerols; C071672:disaccharide tripeptide; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D015474:Isotretinoin